By Katherine Hamilton
Co-Diagnostics withdrew its application to the Food and Drug Administration for a Covid-19 test.
The Salt Lake City diagnostics company said Friday it plans to submit an enhanced version of the test, known as Co-Dx PCR COVID-19 Test. Co-Diagnostics is seeking 501(k) review, which looks at whether a device is safe and effective.
The decision to withdraw is based on discussions Co-Diagnostics had with the FDA about the ability to detect a potential deterioration of one component of the test, related to shelf-life stability, it said. Co-Diagnostics plans to address the issue before re-submitting, it said.
The company aims to collect clinical evaluation data on a new test's performance before submitting it.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 21, 2025 16:32 ET (21:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.